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Bardet–Biedl syndrome (BBS) is a syndromic form of retinal degeneration. Recently, homozygosity mapping
with a consanguineous family with isolated retinitis pigmentosa identiﬁed a missense mutation in BBS3, a
known BBS gene. The mutation in BBS3 encodes a single amino acid change at position 89 from alanine
to valine. Since this amino acid is conserved in a wide range of vertebrates, we utilized the zebraﬁsh
model system to functionally characterize the BBS3 A89V mutation. Knockdown of bbs3 in zebraﬁsh alters
intracellular transport, a phenotype observed with knockdown of all BBS genes in the zebraﬁsh, as well as
visual impairment. Here, we ﬁnd that BBS3 A89V is sufﬁcient to rescue the transport delays induced by
the loss of bbs3, indicating that this mutation does not affect the function of BBS3 as it relates to syndromic
disease. BBS3L A89V, however, was unable to rescue vision impairment, highlighting a role for a speciﬁc
amino acid within BBS3 that is necessary for visual function, but dispensable in other cell types. These
data aid in our understanding of why patients with the BBS3 A89V missense mutation only present with iso-
lated retinitis pigmentosa.
INTRODUCTION
Bardet–Biedl syndrome (BBS, OMIM 209900) is a geneti-
cally heterogeneous autosomal recessive disorder character-
ized by retinitis pigmentosa, obesity, polydactyly, renal
abnormalities, hypogenitalism and cognitive impairment
(1–4). Moreover, BBS is associated with an increased risk for
hypertension, diabetes and heart defects (1,2,5). BBS patients
present with early and progressive photoreceptor degeneration
and are blind by the third decade of life (2,6–13). To date, 12
BBS (BBS1–12) genes are reported to individually cause BBS
(14–27). Additionally, hypomorphic mutations in MKS1 and
CEP290 have been associated with BBS, representing
BBS13 and BBS14, respectively (28). The BBS genes belong
to multiple protein families and function cannot be deﬁned
based on homology; however, recent advances in molecular
pathophysiology and animal models have helped to elucidate
why 14 different genes can lead to the same phenotype.
Work in mouse, zebraﬁsh, Caenorhabditis elegans and Chla-
mydomonas has provided multiple lines of evidence support-
ing a role for BBS proteins in cilia function and
intraﬂagellar and/or intracellular transport (19,22,23,26,29–
36). Although progress has been made in understanding the
pathophysiology of BBS, there are major gaps in our under-
standing of the precise cellular function of the BBS proteins.
BBS3 (ARL6, ADP-ribosylation factor-like), a member of
the Ras family of small GTP-binding proteins, was initially
identiﬁed as a BBS gene through computational genomics
and high-density single nucleotide polymorphism (SNP) geno-
typing (21,22). Several mutations (G2X, T31M, T31R, P108L,
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reported throughout BBS3 (21,22,37). Knockdown of bbs3
using an antisense oligonucleotide [Morpholino (MO)]
results in two cardinal features of BBS in the zebraﬁsh:
reduced size of the ciliated Kupffer’s Vesicle and delays in
intracellular melanosome transport (35,38). These prototypical
phenotypes are preset with knockdown of all BBS genes in the
zebraﬁsh (26,34,35,38). Recently, we identiﬁed a second
longer eye-speciﬁc transcript of BBS3, BBS3L, which is
required for retinal organization and function in both the
mouse and zebraﬁsh (38). Knockdown of either both bbs3
transcripts or bbs3L alone leads to vision impairment in zebra-
ﬁsh. To determine the functional requirement of each tran-
script, RNA encoding either human BBS3 or BBS3L was
co-injected with the bbs3 aug MO, which targets both tran-
scripts. We determined that human BBS3 RNA is sufﬁcient
to suppress the melanosome transport delays, but not the
vision defect. In contrast, BBS3L RNA was sufﬁcient to
rescue the vision defect; however, it was unable to suppress
the cardinal phenotypes of BBS seen in the zebraﬁsh, support-
ing a retina speciﬁc role for BBS3L (38).
BBS is rare in the general population; however, the study of
this disease can offer insight into normal retinal development
as well as provide an understanding of the pathophysiology
involved in non-syndromic forms of BBS. Homozygosity
mapping of a consanguineous Saudi Arabian family has ident-
iﬁed a missense mutation (A89V) in BBS3 that leads to non-
syndromic retinitis pigmentosa (39,40). The identiﬁcation of
speciﬁc mutations in the same gene that results in either syn-
dromic or non-syndromic retinitis pigmentosa will provide
insight into tissue-speciﬁc functional regions of BBS3 in the
retina. Moreover, understanding the functional domains of
proteins involved in vision aids in our understanding of not
only the disease state, but also normal vision development.
Here we report the functional characterization of the BBS3
missense mutation (A89V), which occurs in a highly con-
served region of BBS3. The function of the BBS3 A89V
mutation was evaluated by utilizing gene knockdown of
bbs3 coupled with RNA rescue in the zebraﬁsh. We examined
the intracellular transport of melanosomes, a cardinal feature
of BBS gene knockdown in the zebraﬁsh, and visual function
using a vision startle assay. The A89V mutation can suppress
the melanosome transport defects, but not the vision impair-
ment observed with the loss of bbs3. Thus, the missense
mutation identiﬁed in patients with non-syndromic retinal
degeneration has uncovered an amino acid in BBS3 that is
necessary for vision. The A89V mutation is able to function
in melanosome transport, demonstrating that the mutant
form of the protein retains the ability to function in tissues
typically affected by BBS.
RESULTS
BBS3 conservation and BBS3L mutant expression
Previous homozygosity mapping with a consanguineous
family from Saudi Arabia identiﬁed a novel missense mutation
(A89V) in BBS3 that results in non-syndromic retinitis pig-
mentosa (39,40). Comparison across vertebrate species with
available full-length BBS3 sequences demonstrates that the
A89V mutation occurs in an evolutionarily conserved region
of the protein, suggesting that the alanine at position 89 may
have an essential function within the protein (Fig. 1A). The
location of the mutation upstream of the C-terminus would
impact both BBS3 and BBS3L, as this region is identical
between the two isoforms (Fig. 1B). Additionally, the mis-
sense mutation is located downstream of the phosphate
binding loop (P-loop), which is important for binding tripho-
sphates of the GTP nucleotide (41). To test whether BBS3L
A89V is stably expressed, we performed western blot analysis
on embryos injected with either human myc-tagged BBS3L or
BBS3L A89V RNA. We found that similar to BBS3L, BBS3L
A89V was present through 5 days post-fertilization (dpf)
(Fig. 1C). Thus, the BBS3 A89V missense mutation is in an
evolutionally conserved region of the protein and would be
found in both BBS3 and BBS3L. Moreover, the mutation
does not impact BBSL expression, indicating that the mutation
does not inhibit protein expression.
BBS3 A89V functions in melanosome transport
Knockdown of bbs3 using a MO that targets both transcripts
(bbs3 aug MO) results in intracellular melanosome transport
delay, a phenotype related to syndromic disease and shared
among all BBS genes (26,34,35,38). In response to light or
hormonal stimuli, zebraﬁsh alter their skin pigmentation
through intracellular melanosome transport within the melano-
phores (42–45). To test the rate of cellular trafﬁcking,
6-day-old zebraﬁsh embryos were dark adapted and treated
with epinephrine to induce retrograde melanosome transport
(Fig. 2A). Retrograde transport results in the movement of
the dispersed melanosomes to a perinuclear location
(Fig. 2B). Rescue experiments were performed by co-injecting
RNA encoding human BBS3 or BBS3 A89V with the bbs3 aug
MO. Wild-type embryos demonstrate rapid melanosome
aggregation, averaging 1.45 min, whereas knockdown of
bbs3 leads to a statistically signiﬁcant delay in transport
[analysis of variance (ANOVA) with Tukey, P , 0.01]
(Fig. 2C and Table 1). We previously demonstrated that
human BBS3, but not human BBS3L, can suppress the mela-
nosome transport delays, thus we focused on BBS3 to investi-
gate the role of the A89V mutation in syndromic disease (38).
Similar to BBS3 RNA, co-injection of BBS3 A89V RNA with
the bbs3 aug MO can restore transport times to wild-type
levels (Fig. 2C and Table 1). These results demonstrate that
the BBS3 A89V missense mutation can function to suppress
the cardinal BBS phenotype of intracellular melanosome
transport. This is consistent with the observation that the
human patients harboring the BBS3 A89V mutation do not
present with BBS-related phenotypes, such as obesity, poly-
dactyly, renal anomalies or cognitive impairment.
BBS3L A89V does not function in vision
Both the mouse and zebraﬁsh model systems have demon-
strated that BBS3L is necessary for proper retinal function.
Additionally, rescue experiments in the zebraﬁsh have
shown that human BBS3L is sufﬁcient to suppress the bbs3
aug MO-induced vision defect (38). Since patients with the
BBS3 A89V mutation present with only retinitis pigmentosa,
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vision by co-injecting BBS3L and BBS3L A89V RNA in
bbs3 knockdown embryos. Visual function was evaluated by
using a natural escape response that is elicited when zebraﬁsh
embryos are exposed to rapid changes in light intensity
(38,46). In the vision startle assay, an embryos response to
ﬁve short blocks in bright light are monitored and recorded.
Visually responsive embryos change swimming directions in
response to short blocks of bright light (Fig. 3A). Wild-type
embryos respond on average 3.77 times (Fig. 3B). Cone-rod
homeobox (crx) gene knockdown was used as a control for
vision impairment as crx is necessary for photoreceptor for-
mation in the zebraﬁsh (47,48). crx knockdown embryos
respond an average of 2.39 times, indicative of vision impair-
ment (Fig. 3B) (ANOVA with Tukey, P , 0.01). bbs3 aug
MO-injected embryos show a statistically signiﬁcant reduction
in the number of responses when compared with controls
(Fig. 3B) (ANOVA with Tukey, P , 0.01) (38). Co-injection
of BBS3L RNA with the bbs3 aug MO restored visual respon-
siveness back to wild-type levels, indicating that BBS3L RNA
was sufﬁcient to rescue vision (Fig. 3B). Conversely, BBS3L
A89V RNA was not able to restore visual function back to
wild-type levels as embryos responded on average 1.60
times (Fig. 3B). Western blot analysis conﬁrms expression
of BBS3L A89V through 5 dpf, when the vision assay is per-
formed (Fig. 1C). The inability of BBS3L A89V RNA to
restore vision provides strong functional support that this mis-
sense mutation leads to non-syndromic retinitis pigmentosa.
DISCUSSION
The present study utilizes the zebraﬁsh to examine the func-
tion of BBS3 A89V in intracellular transport, a phenotype
associated with the knockdown of BBS genes, and vision.
This mutation was identiﬁed in a consanguineous Saudi
Figure 1. BBS3 conservation and protein expression. (A) Multi-species alignment of BBS3 demonstrating the conservation among vertebrates. Shaded box high-
lights the location of the A89V mutation. Asterisks (∗) indicate identical amino acids, while colons (:) and periods (.) represent conserved amino acids.
(B) Schematic depicting the location of the A89V mutation in human BBS3 and BBS3L isoforms. Hatched box depicts the location of the P-loop motif and
the grey box on the C-terminus of BBS3L denotes the region of difference between the two isoforms. (C) Western blot analysis of staged zebraﬁsh embryos
injected with either human BBS3L or BBS3L A89V myc-tagged RNA. Both proteins are present through 5 dpf. Actin served as a control.
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(39,40). The polymorphism phenotyping program, PolyPhen,
predicts that the BBS3 A89V missense mutation is a benign
non-synonomous SNP; however, the alanine at position 89 is
highly conserved in vertebrates, suggesting that this amino
acid has an essential function. Using RNA rescue experiments,
we demonstrate that unlike BBS3L RNA, the BBS3L A89V
RNA does not rescue the vision defect observed with the
loss of bbs3. Although the A89V mutation is not functional
in vision, BBS3 A89V RNA is able to suppress the cardinal
zebraﬁsh BBS phenotype of melanosome transport. Taken
together, these data demonstrate that the BBS3 A89V
mutation identiﬁed in patients with non-syndromic retinal
degeneration is critical and speciﬁc for the vision defect.
This study highlights the importance of functionally evaluating
mutations that fall within different splice variants of a single gene
for disease or tissue-speciﬁc relevance. It is estimated that
Figure 2. BBS3 A89V functions in melanosome transport. (A) Schematic illustrating the retrograde movement of melanosomes within the melanocyte from the
periphery before epinephrine treatment to the perinuclear region after epinephrine treatment. (B) Dorsal view of a dark-adapted wild-type 6-day-old zebraﬁsh
embryo. Boxed head region is magniﬁed below the full embryo. The left-hand image shows melanocytes prior to epinephrine treatment, while the right-hand
panel depicts the same melanocytes at the endpoint of retrograde transport. (C) The graph summarizes the average epinephrine-induced response times in
minutes for each experimental group. Both human BBS3 and BBS3 A89V RNAs are able to suppress the transport time seen with knockdown of bbs3.
Sample size (n) is denoted on the X-axis. ∗∗P , 0.01, ANOVA with Tukey. Data presented as the mean+SEM.
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aANOVA and Tukey test, P , 0.01 when compared with bbs3 aug MO.
bANOVA and Tukey test, P , 0.01 when compared with wt.
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(49,50). Multiple splice isoforms with potentially diverse func-
tionscanbegeneratedfromasinglegene,thuscontributingtophe-
notypic complexity in disease. Recently, a retina speciﬁc splice
variant was identiﬁed for another BBS gene, BBS8 (51). A splice-
sitemutationwasidentiﬁedinBBS8thatresultedintheskippingof
a retina speciﬁc exon (51). This mutation results in affected indi-
viduals presenting with non-syndromic retinitis pigmentosa,
similar to what was seen with patients harboring the BBS3
A89V missense mutation (51). While the BBS3 A89V mutation
does not fall within in a splice site, it is located such that it
impacts both the canonical BBS3 isoform as well as the eye-
speciﬁc BBS3L isoform. Thus, mutations targeting a gene with
multiple isoforms can have different affects on disease presen-
tation.
Our ﬁnding that the BBS3 A89V missense mutation is
speciﬁc for vision demonstrates that this region is important
for proper function of the protein in the eye. While no
known domains are predicated to map to this region of
BBS3, it is possible that the A89V mutation abrogates the
interaction of BBS3 with a retina speciﬁc modiﬁer and/or
retina speciﬁc binding partner. Mutations in another BBS
gene, CEP290, also result in phenotypic variation. This gene
has been implicated in numerous diseases, in particular BBS
and isolated blindness (52). While this gene has been impli-
cated in several syndromic diseases, a mouse model for
Cep290, the rd16 mouse in which a few exons of the gene
are missing, only manifests early onset retinal degeneration
(53). Moreover, additional splice isoforms are predicted for
Cep290 and western blot analysis supports the notion that
there are retina speciﬁc isoforms (53). These observations
for BBS8, Cep290 and now BBS3 indicate that mutations
need to be evaluated in the context of both isoform and
tissue speciﬁcity. Moreover, this study highlights the impor-
tance of functionally testing human disease mutations to
further elucidate their underlying pathophysiology in disease.
MATERIALS AND METHODS
Ethics statement
The University Animal Care and Use Committee at the
University of Iowa approved all animal work in this study.
Figure 3. The BBS3L A89V mutation is not functional in vision. (A) Still images of a 5-day-old zebraﬁsh embryo illustrating the characteristic escape response
elicited by a sudden change in light intensity. The white boxes below the stills indicate lights on, while the grey box indicates lights off. For visualization of the
embryo in the dark, image contrast manipulation was performed in Adobe Photoshop. (B) Graphical representation of the vision startle response data. crx gene
knockdown was used as a control for visual impairment. Human BBS3L can rescue the vision defect, whereas human BBS3L A89V is not able to rescue the vision
defect in bbs3 knockdown embryos. The sample size (n) is noted on the X-axis. ∗∗P , 0.01, ANOVA with Tukey. Data presented as the mean+SEM.
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Adult zebraﬁsh were maintained under standard conditions
and embryos collected from natural spawnings (54).
Embryos were staged using previously described criteria (55).
Conservation
Using the Ensemble genome (release 59), orthologs to BBS3
were identiﬁed by performing BLAST algorithms with the
human BBS3 sequence (ENST00000335979). Sequences
were aligned using ClustalW (56).
Morpholino injections
Antisense MOs were air pressure injected into one- to
four-cell-staged embryos at a concentration of 12 ng for





DNA constructs and RNA synthesis
The A89V mutation was generated by introducing the appro-
priate nucleotide change into C-terminally myc-tagged
human BBS3 or BBS3L constructs using the Quick Change






RNA was synthesized using the mMessage mMachine tran-
scription kit (Ambion) and injected into 1–2 cell embryos at a
concentration of 8 pg.
Melanosome transport assay
The melanosome transport assay was performed as previously
described (26,34,35). Brieﬂy, epinephrine (500 ml/ml, Sigma
E437) treatment was applied to dark-adapted 6-day-old zebra-
ﬁsh embryos. The movement of the melanosomes from the
periphery to the perinuclear region was timed and recorded.
A stereoscope equipped with a Zeiss Axiocam camera was
used to image live embryos.
Vision startle response
Zebraﬁsh embryos change swimming directions in response to
rapid changes in light intensity. Prior to performing the vision
startle assay, 5 dpf embryos are light adapted for 1 h. Embryos
were exposed to ﬁve trials of rapid changes in light intensity
spaced at 30 s intervals and the response, a distinct C-bend,
scored (38,57). crx gene knockdown was used as a control
for vision impairment. To ensure motility, embryos were
probed with a blunt needle on their ﬂank, invoking the same
response observed in the vision assay.
Statistical analysis
Statistics for both the melanosome transport and vision startle
assay were calculated using the one-way ANOVA paired with
the Tukey honestly signiﬁcant difference test.
Western blot
Embryos were injected with C-terminal myc-tagged human
BBS3L (8pg) and BBS3L A89V (8pg) RNA at the 1–2 cell
stage. Embryos (n ¼ 15) were collected at the following time
points: 72 hpf, 4 dpf and 5 dpf. Collected embryos were hom-
ogenized in lysis buffer [20 mM Tris; 100 mM NaCl; 1 mM
EDTA (ethylenediaminetetraacetic acid); 0.5% Triton X-100;
0.5% SDS (sodium dodecyl sulfate)] with protease inhibitor
[0.1 mM PMSF (phenylmethanesulfonyl ﬂuoride, Roche);
10 mg/ml Leupeptin (Roche)] and the supernatant collected.
Whole cell lysates were run and transferred using the X Cell
SureLock Mini-Cell System under reduced conditions (Invitro-
gen). Samples were mixed with NuPAGE LDS Sample Buffer
and NuPAGE Reducing Agent (Invitrogen), heated at 708C for
10 min and run on a pre-cast 4–12% NuPAGE Novex Bis-Tris
gel (Invitrogen). Protein was transferred to a PVDF membrane
(polyvinylidene ﬂuoride, Amersham). The membrane was
blocked in 5% milk (Carnation) for 1 h and probed with either
mouse monoclonal anti-Myc (1:2000, 9B11, Cell Signaling) or
rabbit polyclonal anti-actin (1:2000, Sigma) antibody overnight
at 48. Horseradish peroxidase-conjugated species-speciﬁc sec-
ondary antibodies (1:10,000, Jackson ImmunoResearch) were
used for detection of primary antibodies.
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